

Oral Presentation Program

Session	Date and Time Room	Chairs	Presentation Number	Presenter	Presentation Title
Oral Presentation 1 Absorption	November 17 (Tue.) 9:30-10:30 Room C 2F Conference Room 202	Hideki Hirabayashi (T.N.Technos) Yoshiyuki Shirasaka (Showa Pharmaceutical University)	01-1	Katsutoshi Yamaguchi	Improving the bioavailability of heterobifunctional molecules by solubilized formulations
			01-2	Reiji Negoya	Integrating Mechanistic and Machine Learning Models for the Prediction of Subcutaneous Antibody Bioavailability
			01-3	Takuto Niino	Comparative Evaluation of Human Pharmacokinetics Prediction Using PBBM and In Vivo Predictive Dissolution Systems
			01-4	Naohiro Aoyama	Evaluation of oral bioavailability of heterobifunctional molecules using modified Caco-2 assay and other physicochemical parameters
			01-5	XICHEN SUN	Toward a Generalized PBBM for HPMC-AS-Based Amorphous Solid Dispersion Drug Products
Oral Presentation 2 Toxicity, Pharmacogeneti cs/Biomarkers, Microphysiologic al Systems (Organs on a Chip)	November 17 (Tue.) 9:30-10:45 Room D 1F Conference Room 101	Raku Shinkyo (Eisai) Masatoshi Tomi (Keio University)	02-1	Shota Koishi	Development of a pancreatic cancer-on-a-chip model for CAF-targeted therapy
			02-2	Sakura Mama	Human blood-brain barrier microfluidic model for visualizing brain metastatic process
			02-3	Takumi Tanaka	Time-Course Profiles of Multiple Renal Biomarkers and Their Association with Pharmacokinetics in a Rat Model of Cisplatin-Induced Nephrotoxicity
			02-4	Shota Nishihara	Beyond the exome: intronic CYP2D6 variants in a Japanese population cause aberrant RNA splicing and loss of enzyme function
			02-5	Suguru Asaji	Mechanistic insights into drug-induced gastrointestinal toxicity mediated by the intestinal serotonin-gut microbiota axis: implications for interindividual variability
			02-6	Takeshi Susukida	Effects of a ketogenic diet on CD8 ⁺ T cell effector responses of HLA-associated drug hypersensitivity reactions
Oral Presentation 3 AI/Bioinformatic s/Omics, Bioimaging/Bioa nalysis	November 17 (Tue.) 10:40-11:30 Room C 2F Conference Room 202	Koya Sato (Astellas Pharma) Sumio Ohtsuki (Kumamoto University)	03-1	Yuki Maeda	Comprehensive proteomic analysis of human postmortem brain to elucidate molecular pathology associated with APOE4, the strongest genetic risk factor for Alzheimer's disease
			03-2	Kaori Wakuya	Development of LC-MS-based analytical method for detection of biotransformation in bevacizumab
			03-3	Yuchen Sun	Development and validation of a rapid and sensitive one-pot hybridization LC-MS method for mipomersen, a gapmer antisense oligonucleotide
			03-4	Aki Ogita	Construction of a multiplex PRM panel for comprehensive quantitative profiling of mouse brain microvascular proteins

Oral Presentation Program

Session	Date and Time Room	Chairs	Presentation Number	Presenter	Presentation Title
Oral Presentation 4 Drug Metabolism Enzymes, Drug- Drug Interactions	November 17 (Tue.) 14:15-15:15 Room D 1F Conference Room 101	Kousei Ito (Chiba University) Miki Nakajima (Kanazawa University)	O4-1	Ferbian Milas Siswanto	Aging-associated remodeling of the skeletal muscle CYPome: comparison with D-galactose-induced senescence in rats
			O4-2	Nao Ezaki	Mutual functional modulation between Ugt2b1 and Cyp3a in mice
			O4-3	Yuma Suzuki	From One Year to One Month: A Cell-Based High-Throughput Platform for Kinetic Analysis of CYP Variants
			O4-4	Chiaki Sugawara	Comparison of Protein Expression Profiles Between Human Intestinal Tissue-Derived Cultured Cells and Their Tissue of Origin and Evaluation of Drug Intestinal Metabolism Prediction Accuracy
			O4-5	Keiichiro Nakamura	Quantitative functional evaluation of PXR-mediated induction of intestinal drug metabolizing enzymes and transporters using a human intestinal epithelial cell model
Oral Presentation 5 Drug-Drug Interactions, Transporters	November 17 (Tue.) 15:25-16:25 Room D 1F Conference Room 101	Yoshitane Nozaki (Eisai) Katsuhisa Inoue (Tokyo University of Pharmacy and Life Sciences)	O5-1	Ryota Ono	Characterization of CSF disposition of organic cations and PGE2 based on species differences in OCT2/OCT3 expression and high expression of OAT3/Cx43 at the blood–arachnoid barrier
			O5-2	Hirokazu Sekiba	Hyper-glycosylation of intestinal P-glycoprotein associated with reduced intrinsic activity in irinotecan-induced gastrointestinal damage
			O5-3	Ruth Shekina Lumumba	Effect of <i>ABCG2</i> c.421C>A (Q141K) variant on pazopanib pharmacokinetics is primarily attributable to intestinal ABCG2
			O5-4	Momoka Kondo	Molecular mechanisms underlying blood-brain barrier transport of Porphyromonas gingivalis outer membrane vesicles
			O5-5	Reiko Takahashi	P-Glycoprotein-Mediated Interactions Between Testosterone and Drugs at the Blood-Brain Barrier
Oral Presentation 6 Transporters	November 18 (Wed.) 9:30-10:30 Room C 2F Conference Room 202	Yoshihisa Shitara (Sanofi) Yukio Kato (Kanazawa University)	O6-1	Takeo Nakanishi	Mechanism of prostaglandin transport by SLCO2A1
			O6-2	Daiki Masui	Utilization of Human Jejunal Spheroid-Derived Differentiated Intestinal Epithelial Cells for the Functional Analyses of Basolateral Efflux Transporters
			O6-3	Keisuke Sato	Effects of OAT2/SLC22A7 on the cellular uptake and metabolism of nicotinic acid riboside
			O6-4	Sumito Ito	Revisiting the Fundamental Assumption of the Relative Expression Factor (REF) Approach for Canalicular ABC Transporters
			O6-5	Saki Izumi	PBPK Analysis of Cyclosporin A-Mediated Time-Dependent Inhibition of OATP1B1: Interpretation of Inhibition Mechanism Using Top-Down and Middle-Out Approaches

Oral Presentation Program

Session	Date and Time Room	Chairs	Presentation Number	Presenter	Presentation Title
Oral Presentation 7 Systems Pharmacology/P harmacometrics	November 18 (Wed.) 10:40-11:40 Room C 2F Conference Room 202	Koji Chiba (Yokohama University of Pharmacy) Kiyomi Ito (Musashino University)	07-1	Meigang Lu	Population pharmacokinetic and exposure-response analysis of ustekinumab in inflammatory bowel disease to identify a real-world target trough concentration
			07-2	Haruka Ide	Receptor-Occupancy Modeling of Caffeine Therapy in Preterm Infants Considering Developmental Stage
			07-3	Akira Kazaoka	Limits of Parameter Compensation for Kp Misestimation in Non-Eliminating Organs During PBPK Modeling of OATP1B Substrates Without Intravenous Data
			07-4	Atsuko Tomaru	Top-Down Identification of Elementary Clearance Processes Governing Human Enterohepatic Circulation Using a Mechanistic PBPK Model Coupled with CGNM
			07-5	Yoshiko Tomita	PBPK modeling of endogenous endothelin-1 and endothelin receptor antagonists to predict receptor subtype occupancy
Oral Presentation 8 Drug Delivery System	November 19 (Thu.) 9:30-10:55 Room C 2F Conference Room 202	Syunsuke Yamamoto (Chugai Pharmaceutical) Tomomi Furihata (Tokyo University of Pharmacy and Life Sciences)	08-1	Shinji Nakayama	Novel approach for direct drug delivery to the central nervous system via intratympanic administration
			08-2	Taichi Ono	Identification of AE2 as a Target for Biopharmaceutical Delivery across the Blood–Cerebrospinal Fluid Barrier
			08-3	Yichen Zhang	Glycosylphosphatidylinositol (GPI)-Anchor-Deleted PH20 mRNA-Loaded Lipid Nanoparticles (LNP) Enhance Hyaluronic Acid (HA) Degradation in Tumor Spheroids
			08-4	Chongjie Zhang	Development of therapy for colorectal peritoneal dissemination by hyaluronic acid degradation by mRNA-loaded lipid nanoparticles via intraperitoneal administration
			08-5	Naoki Saito	Development of a Novel Functional Assay Method for the Lysosomal Transporter Sialin
			08-6	Shoichiro Fukuda	Development of ionic liquid-based oral peptide delivery system: effect of controlling gastric acid on intestinal absorption of semaglutide
			08-7	Natsumi Watanabe	SLS peptide-modified anionic liposomes for enhanced transport in a human <i>in vitro</i> blood–brain barrier model